Novartis's Results Look Impressive -- Market Talk

Dow Jones

Jul 17, 2025

0702 GMT - Novartis reported impressive results, extending a stretch of quarterly updates in which it beat expectations and raised guidance to a tenth quarter, Vontobel's Stefan Schneider says. The Swiss pharmaceutical company reported second-quarter core operating profit of $5.925 billion, up 21% at constant currency. This exceeded both consensus expectations and Vontobel's estimate, the analyst says in a research note. Novartis now expects core operating profit to grow by a low-teens percentage this year, having previously forecast an increase by low double digits. This guidance lift came as a surprise ahead of the anticipated arrival of generic competition for Novartis's heart drug Entresto--the group's best-selling medicine--in the U.S., Schneider says. Novartis shares closed at 95.12 Swiss francs on Wednesday. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 17, 2025 03:02 ET (07:02 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2552102612"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552102612\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552102612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 15:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552102612","market":"sg","top_or_hot":-1,"title":"Novartis's Results Look Impressive -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0702 GMT - Novartis reported impressive results, extending a stretch of quarterly updates in which it beat expectations and raised guidance to a tenth quarter, Vontobel's Stefan Schneider says. The Swiss pharmaceutical company reported second-quarter core operating profit of $5.925 billion, up 21% at constant currency. This exceeded both consensus expectations and Vontobel's estimate, the analyst says in a research note. Novartis now expects core operating profit to grow by a low-teens percentage this year, having previously forecast an increase by low double digits. This guidance lift came as a surprise ahead of the anticipated arrival of generic competition for Novartis's heart drug Entresto--the group's best-selling medicine--in the U.S., Schneider says. Novartis shares closed at 95.12 Swiss francs on Wednesday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 03:02 ET (07:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis's Results Look Impressive -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis's Results Look Impressive -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-17 15:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0702 GMT - Novartis reported impressive results, extending a stretch of quarterly updates in which it beat expectations and raised guidance to a tenth quarter, Vontobel's Stefan Schneider says. The Swiss pharmaceutical company reported second-quarter core operating profit of $5.925 billion, up 21% at constant currency. This exceeded both consensus expectations and Vontobel's estimate, the analyst says in a research note. Novartis now expects core operating profit to grow by a low-teens percentage this year, having previously forecast an increase by low double digits. This guidance lift came as a surprise ahead of the anticipated arrival of generic competition for Novartis's heart drug Entresto--the group's best-selling medicine--in the U.S., Schneider says. Novartis shares closed at 95.12 Swiss francs on Wednesday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 03:02 ET (07:02 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2552102612","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552102612","pubTimestamp":1752735720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0702 GMT - Novartis reported impressive results, extending a stretch of quarterly updates in which it beat expectations and raised guidance to a tenth quarter, Vontobel's Stefan Schneider says. The Swiss pharmaceutical company reported second-quarter core operating profit of $5.925 billion, up 21% at constant currency. This exceeded both consensus expectations and Vontobel's estimate, the analyst says in a research note. Novartis now expects core operating profit to grow by a low-teens percentage this year, having previously forecast an increase by low double digits. This guidance lift came as a surprise ahead of the anticipated arrival of generic competition for Novartis's heart drug Entresto--the group's best-selling medicine--in the U.S., Schneider says. Novartis shares closed at 95.12 Swiss francs on Wednesday. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4578":"CAR-T","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","NVS":"诺华","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"诺华的业绩看起来令人印象深刻——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":0.9},"content_text":"0702 GMT - Novartis reported impressive results, extending a stretch of quarterly updates in which it beat expectations and raised guidance to a tenth quarter, Vontobel's Stefan Schneider says. The Swiss pharmaceutical company reported second-quarter core operating profit of $5.925 billion, up 21% at constant currency. This exceeded both consensus expectations and Vontobel's estimate, the analyst says in a research note. Novartis now expects core operating profit to grow by a low-teens percentage this year, having previously forecast an increase by low double digits. This guidance lift came as a surprise ahead of the anticipated arrival of generic competition for Novartis's heart drug Entresto--the group's best-selling medicine--in the U.S., Schneider says. Novartis shares closed at 95.12 Swiss francs on Wednesday. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2025 03:02 ET (07:02 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}